Safe S.A. specializes in the design, manufacture and marketing of medical devices for spine surgery. The company offers implants and instruments in the range of SteriSpine (the first spinal arthrodesis system that is for single use and is sterile and totally traceable). The group's activity is organized around 2 areas: - direct and indirect sales of medical devices (Safe Orthopaedics): business carried out in France, Germany, the United Kingdom, the United States and South America; - subcontracted manufacturing services for orthopedic medical devices (Safe Medical).

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	128K 144K 119K 108K 205K 13.8M 206K 1.44M 558K 7.05M 539K 527K 22.64M	P/E 2024 *	-	P/E 2025	-0.07x
Enterprise Value	13.24M 14.9M 12.36M 11.26M 21.24M 1.43B 21.44M 150M 57.95M 732M 55.95M 54.73M 2.35B	EV / Sales 2024	2.39x	EV / Sales 2025	2.47x
Free-Float	87.27%	Yield 2024 *	-	Yield 2025	-

30/06	Safe Group sharply improves its full-year results
29/06	Safe Orthopaedics SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
29/05	Safe And ABL Alpstein Sign Exclusive Distribution Agreement For SteriSpine Range In Peru	CI
29/05	Safe Group enters Peru with exclusive distribution agreement
16/03	Changes to the SAFE Board of Directors
17/12	Safe Orthopaedics Signs Exclusive Distribution Agreement for Spanish Market	MT
17/12	Safe Group Signs Strategic Distribution Agreement in Spain with Vortrom Biologics	CI
01/12	Safe Orthopaedics SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/07/25	Alert wrongly tagged to Safe SA withdrawn	RE
28/12/24	Safe Orthopaedics SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
09/09/24	The market burns its idols
06/02/24	Safe: wins its appeal against Neo Medical
28/12/23	Safe: audit initiated for a turnaround plan

22/12	SAFE, SPONSOR OF THE 12TH MAMMI INTERNATIONAL CONFERENCE IN ITALY	GL
17/12	SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS	GL
17/12	SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS	AQ
09/09/24	New bond financing agreement in a minimum amount of €3 million in anticipation of validation of the continuation plan	GL
25/11/23	Safe group announces the convocation of the Annual General Meeting of Shareholders to be held on December 15th 2023 and provides an update on the situation	AQ

09/09	SAFE : point sur l'audience du 7 septembre 2026 devant le Tribunal des activités économiques de Lyon
26/08	SAFE Group : point sur la suspension de cotation et sur la certification des comptes annuels 2025
30/06	Safe Group améliore nettement ses résultats annuels
29/05	Safe Group s'implante au Pérou avec un accord de distribution exclusif
29/04	Safe S A : Report de la publication des résultats annuels 2025 de SAFE Group

Manager	Title	Age	Since
Nicolas Papillon CEO	Chief Executive Officer	46	-
Thomas Droulout CTO	Chief Tech/Sci/R&D Officer	50	15/02/2010
François-Henri Reynaud DFI	Director of Finance/CFO	-	09/11/2017

Safe Orthopaedics Stock Euronext Paris

Stocks

Medical Equipment, Supplies & Distribution

Valuation: Safe Orthopaedics

Latest news: Safe Orthopaedics

Press Releases: Safe Orthopaedics

News in other languages: Safe Orthopaedics

Quotes and Performance

Managers and Directors: Safe Orthopaedics

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Thomas Droulout BRD	Director/Board Member	50	-
François-Henri Reynaud BRD	Director/Board Member	-	26/11/2019
Ismaël Nujurally BRD	Director/Board Member	69	26/11/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SAFE ORTHOPAEDICS	-0.79%	-8.36%	-	-	144K
ABBOTT LABORATORIES	+0.84%	-3.74%	-27.56%	+1.93%	169B
MEDTRONIC PLC	-0.07%	-2.55%	-11.59%	+13.26%	110B
STRYKER CORPORATION	+0.90%	+1.13%	-25.66%	+3.47%	106B
ESSILORLUXOTTICA	-1.24%	-0.76%	-49.50%	-12.46%	73.87B
CENCORA, INC.	-0.24%	+0.69%	+2.08%	+69.19%	58.98B
HOYA CORPORATION	+1.82%	+4.18%	+8.91%	+62.37%	51.28B
BECTON, DICKINSON AND COMPANY	-0.71%	-3.82%	-8.68%	-31.93%	48.16B
IDEXX LABORATORIES, INC.	+0.12%	-0.17%	-17.87%	+19.66%	40.84B
DEXCOM, INC.	-1.01%	-1.45%	+27.31%	-2.67%	32.21B
Average	-0.06%	-0.86%	-11.40%	+13.65%	76.69B
Weighted average by Cap.	+0.21%	-1.30%	-17.37%	+11.15%

	2024	2025
Net sales	5.04M 5.67M 4.7M 4.29M 8.09M 545M 8.16M 56.94M 22.06M 279M 21.3M 20.84M 895M	5.36M 6.04M 5.01M 4.56M 8.61M 580M 8.69M 60.59M 23.48M 297M 22.67M 22.17M 952M
Net income	-1.93B -2.17B -1.8B -1.64B -3.1B -209B -3.12B -21.79B -8.44B -107B -8.15B -7.98B -342B	-4.67M -5.26M -4.36M -3.98M -7.5M -506M -7.57M -52.79M -20.46M -259M -19.75M -19.32M -830M
Net Debt	11.47M 12.91M 10.71M 9.76M 18.4M 1.24B 18.58M 130M 50.21M 634M 48.47M 47.42M 2.04B	13.11M 14.76M 12.24M 11.15M 21.04M 1.42B 21.23M 148M 57.39M 725M 55.41M 54.2M 2.33B